The International Myeloma Foundation Brings the Patient Voice and Science to FDA-ODAC Meeting; Advocates for BLENREP® (belantamab mafodotin) in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/odac-blenrep-advisory-meeting)